CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Regulatory News: Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (ALCLS.PA) (ALCLS.PA), announces that it has been awarded a second contract to provide services to the National Institutes of Health (NIH) and certain other government agencies.
This multiple award, indefinite delivery/indefinite quantity (IDIQ) contract, has a maximum order limit of $6,9 million over a period of three years.
Under the terms of the contract, the scope of work includes generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells toward specific tissue cell type for research use.
This second major contract following the one announced October 16th further reaffirms Cellectis Group’s expertise. We saw since 2010 the huge potential of investment in license agreements for Professor Yamanaka’s iPS patents. Furthermore Professor Shinya Yamanaka has been awarded the 2012 Nobel Prize in Medicine.
“The second contract won through a NIH call for tenders dedicates our company as a leading competitor and an expert in the field in the United States,” said Marc Le Bozec, CEO of Cellectis bioresearch.
André Choulika, CEO of Cellectis declared: "This contract award granted by the most prestigious US research organization the NIH is a great recognition for Cellectis Group as the world's largest biotech for the design, manufacture and engineer of human cells and cell lines for the drug discovery and development.”
About Cellectis bioresearch
Established in 2008 as a subsidiary of Cellectis, Cellectis bioresearch provides life sciences researchers with genome customization tools and services, such as the award-winning TALEN™ Access™. The company also develops and markets genetically customized cells with characteristics and performances adapted to three main markets: drug discovery, gene function studies and protein production.
For further information, please visit www.cellectis-bioresearch.com
Founded in France in 1999, the Cellectis Group is based on a highly specific DNA engineering technology. Its application sectors are human health, agriculture and bio-energies. Co-created by André Choulika, its Chief Executive Officer, Cellectis is today one of the world leading companies in the field of genome engineering. The Group has a workforce of 230 employees working on 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in the United States. Cellectis achieved in 2011 €16M revenues and has signed more than 80 industrial agreements with pharmaceutical laboratories, agrochemical and biotechnology companies since its inception. AFM, Dupont, BASF, Bayer, Total, Limagrain, Novo Nordisk… are some of the Group’s clients and partners.
Since 2007, Cellectis has been listed on NYSE-Euronext Alternext market (ALCLS.PA) in Paris.
For more information, visit our website: www.cellectis.com
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
For further information:
Philippe Valachs, +33 (0)1 81 69 16 00
Cyril Combe / Marie-Anne Garigue, +33 (0)1 53 65 68 68